An NCCN very high risk localized Prostate cancer patient at diagnosis who is in the biochemical recurrence stage...
I apologize, but I don't see specific NCCN guidelines in the provided source material that directly address prognosis and treatment options for very high risk localized prostate cancer with biochemical recurrence. To provide accurate, evidence-based guidance for your specific situation, I would need to reference the current NCCN Guidelines for Prostate Cancer.
What I can say with confidence is that treatment decisions for biochemical recurrence of prostate cancer should be made in consultation with your oncology team, taking into account several factors including:
- Your specific PSA dynamics (which you've noted includes a PSA doubling time >15 months)
- Your prior treatments
- Your overall health status
- Your preferences regarding potential side effects and quality of life considerations
The choice between conventional ADT monotherapy versus newer combination approaches like dual hormone therapy or experimental approaches like Bipolar Androgen Therapy requires careful discussion with prostate cancer specialists who can review the most current clinical evidence for your specific situation.
I recommend:
- Consulting with your oncologist to review current NCCN guidelines specific to your case
- Considering getting a second opinion from a prostate cancer specialist at a major cancer center
- Discussing the pros and cons of each treatment approach, including potential side effects and impact on quality of life
Would you like me to provide information about what questions to ask your healthcare team when discussing these treatment options?
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Prostate Cancer — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Question asked:
I am an NCCN very high risk localized Prostate cancer patient at diagnosis who is in the biochemical recurrence stage with a PSA Doubling Time of greater than 15 months. What is my prognosis? And should I get conventional ADT monotherapy or modern double hormone (Lupron and Enzalutamide) blockade or a novel supraphysiologic testosterone Bipolar Androgen Therapy approach?
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Prostate Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for Prostate Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Prostate Cancer
- What does my Prostate Cancer diagnosis mean and what should I know first
- What is the standard of care for early stage Prostate Cancer according to NCCN guidelines
- For my localized/regional stage, what are the pros and cons of the different management options (e.g., active...
- Please provide a comprehensive summary of NCCN guidelines for my Prostate Cancer stage Stage III cancer. What are...
- What are the early signs of Prostate Cancer recurrence
- What are my workplace rights after a Prostate Cancer diagnosis
- Should I get a second opinion on my Prostate Cancer diagnosis
- How do I talk to my family about my Prostate Cancer diagnosis